The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: A two-year observational study in the Sunnybrook dementia cohort

International Psychogeriatrics

Volumn 20, Issue 6, 2008, Pages 1141-1159

  Behl, Pearl ^a,b   Lanctôt, Krista L ^a,b   Streiner, David L ^a,b,c   Black, Sandra E ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Alzheimer's disease; Basic ADL; Disability Assessment for Dementia Scale (DAD); Executive function; Functional decline; Instrumental ADL

Indexed keywords

CHOLINESTERASE INHIBITOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DETERIORATION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; COHORT STUDIES; COST OF ILLNESS; FEMALE; GERIATRIC ASSESSMENT; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; OBSERVATION; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 54049139574     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610208007540     Document Type: Article

References (31)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. Washington DC: American Psychiatric Association.
2. Behl, P., Lanctot, K. L., Streiner, D. L., Guimont, I. and Black, S. E. (2006). Cholinesterase inhibitors slow decline in executive functions, rather than memory, in Alzheimer's disease: a 1-year observational study in the Sunnybrook dementia cohort. Current Alzheimer Research, 3, 147-156.
3. Boyle, P. A. (2004). Assessing and predicting functional impairment in Alzheimer's disease: the emerging role of frontal system dysfunction. Current Psychiatry Reports, 6, 20-24.
4. Boyle, P. A., Malloy, P. F., Salloway, S., Cahn-Weiner, D. A., Cohen, R. and Cummings, J. L. (2003). Executive dysfunction and apathy predict functional impairment in Alzheimer disease. American Journal of Geriatric Psychiatry, 11, 214-221.
5. Courtney, C. et al. (2004). Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet, 363, 2105-2115.
6. Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Emir, B., Mastey, V. and Subbiah, P. (2003). Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. Journal of the American Geriatrics Society, 51, 737-744.
7. Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P. and Whalen, E. (2001). A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 57, 613-620.
8. Geldmacher, D. S., Provenzano, G., McRae, T., Mastey, V. and Ieni, J. R. (2003). Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. Journal of the American Geriatrics Society, 51, 937-944.
9. Gelinas, I., Gauthier, L., McIntyre, M. and Gauthier, S. (1999). Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. American Journal of Occupational Therapy, 53, 471-481.
10. Gelinas, I., Gauthier, S. and Cyrus, P. A. (2000). Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living. Journal of Geriatric Psychiatry and Neurology, 13, 9-16.
11. Glosser, G., Gallo, J., Duda, N., de Vries, J. J., Clark, C. M. and Grossman, M. (2002). Visual perceptual functions predict instrumental activities of daily living in patients with dementia. Neuropsychiatry, Neuropsychology, and Behavioral Neurology, 15, 198-206.
12. Holland, B. S. and Copenhaver, M. D. (1988). Improved Bonferroni-type multiple testing procedures. Psychological Bulletin, 104, 145-149.
13. Karaman, Y., Erdogan, F., Koseoglu, E., Turan, T. and Ersoy, A. O. (2005). A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 19, 51-56.
14. Khang, P., Weintraub, N. and Espinoza, R. T. (2004). The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available? Journal of the American Medical Directors Association, 5, 249-255.
15. Lanctôt, K. L. et al. (2003). Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Canadian Medical Association Journal, 169, 557-564.
16. Lingler, J. H., Martire, L. M. and Schulz, R. (2005). Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis. Journal of the American Geriatrics Society, 53, 983-990.
17. Lopez, O. L., Becker, J. T., Saxton, J., Sweet, R. A., Klunk, W. and DeKosky, S. T. (2005). Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. Journal of the American Geriatrics Society, 53, 83-87.
18. Lopez, O. L., Becker, J. T., Wisniewski, S., Saxton, J., Kaufer, D. I. and DeKosky, S. T. (2002). Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 72, 310-314.
19. Marshall, G. A., Fairbanks, L. A., Tekin, S., Vinters, H. V. and Cummings, J. L. (2006). Neuropathologic correlates of activities of daily living in Alzheimer disease. Alzheimer Disease and Associated Disorders, 20, 56-59.
20. Mattis, S. (1976). Mental status examination for organic mental syndrome in the elderly patient. In L. Bellak and T.B. Karasu (eds.), Lezak Neuropsychological Assessment (pp. 739-740). New York: Grune & Stratton.
21. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
22. Mesulam, M. (2004). The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learning and Memory, 11, 43-49.
23. Mohr, E., Feldman, H. and Gauthier, S. (1995). Canadian guidelines for the development of antidementia therapies: a conceptual summary. Canadian Journal of Neurological Sciences, 22, 62-71.
24. Mohs, R. C. et al. (2001). A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 57, 481-488.
25. Perry, R. J. and Hodges, J. R. (1999). Attention and executive deficits in Alzheimer's disease: a critical review. Brain, 122, 383-404.
26. Perry, R. J. and Hodges, J. R. (2000). Relationship between functional and neuropsychological performance in early Alzheimer disease. Alzheimer Disease and Associated Disorders, 14, 1-10.
27. Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P. and Damaraju, C. V. (2004). The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Archives of Neurology, 61, 252-256.
28. Severson, M. A. et al. (1994). Patterns and predictors of institutionalization in community-based dementia patients. Journal of the American Geriatrics Society, 42, 181-185.
29. Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S. and Ding, C. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology, 54, 2269-2276.
30. Teri, L., Borson, S., Kiyak, H. A. and Yamagishi, M. (1989). Behavioral disturbance, cognitive dysfunction, and functional skill. Prevalence and relationship in Alzheimer's disease. Journal of the American Geriatrics Society, 37, 109-116.
31. Winblad, B. et al. (2001). A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology, 57, 489-495.